Menu
GIVE THEM MORE QUALITY TIME TO LIVE
GIVE THEM MORE QUALITY TIME TO LIVE
.png?width=1920&height=1437&format=webp&quality=50 "image")
POWER PROVEN BY ADDITIONAL EVIDENCE1
IT'S HERE: The TITAN final analysis confirms the power of ERLEADA® + ADT to push back on progression.1
After 44 months of median follow-up, the analysis confirms a range of benefits for a broad population of patients with mHSPC.1
IT'S HERE: The TITAN final analysis confirms the power of ERLEADA® + ADT to push back on progression.1
After 44 months of median follow-up, the analysis confirms a range of benefits for a broad population of patients with mHSPC.1
References:
1. Chi KN, et al. Final analysis results from TITAN: a phase 3 study of apalutamide (APA) vs placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (AOT). Available at: https://meetinglibrary.asco.org/reoord/194577/abstract. Accessed: February 2021.
1. Chi KN, et al. Final analysis results from TITAN: a phase 3 study of apalutamide (APA) vs placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (AOT). Available at: https://meetinglibrary.asco.org/reoord/194577/abstract. Accessed: February 2021.
CP-212200
